uniQure (NASDAQ:QURE) Director Sells $174,319.20 in Stock

uniQure N.V. (NASDAQ:QURE) Director Jack Kaye sold 6,390 shares of uniQure stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $27.28, for a total value of $174,319.20. Following the completion of the sale, the director directly owned 20,439 shares in the company, valued at approximately $557,575.92. This represents a 23.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Jack Kaye also recently made the following trade(s):

• On Tuesday, November 4th, Jack Kaye sold 38,810 shares of uniQure stock. The stock was sold at an average price of $30.34, for a total value of $1,177,495.40.

uniQure Stock Down 9.0%

Shares of NASDAQ QURE traded down $2.28 during midday trading on Monday, reaching $23.04. The company’s stock had a trading volume of 2,769,583 shares, compared to its average volume of 2,067,594. The stock has a 50 day simple moving average of $25.46 and a 200-day simple moving average of $27.61. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of -5.25 and a beta of 0.68. uniQure N.V. has a fifty-two week low of $7.76 and a fifty-two week high of $71.50.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.53). uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. The business had revenue of $3.70 million during the quarter, compared to analyst estimates of $4.46 million. Equities research analysts predict that uniQure N.V. will post -3.75 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on QURE shares. Benchmark reissued a “buy” rating on shares of uniQure in a research report on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of uniQure in a research note on Wednesday, October 8th. HC Wainwright decreased their target price on shares of uniQure from $110.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, November 4th. Stifel Nicolaus lowered their target price on shares of uniQure from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Thursday, December 11th. Finally, Royal Bank Of Canada cut their price target on shares of uniQure from $65.00 to $45.00 and set an “outperform” rating for the company in a research note on Monday, November 3rd. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $60.82.

Hedge Funds Weigh In On uniQure

Large investors have recently modified their holdings of the stock. Private Trust Co. NA bought a new stake in shares of uniQure during the 3rd quarter worth about $28,000. Jones Financial Companies Lllp lifted its position in uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 509 shares during the last quarter. CIBC Private Wealth Group LLC bought a new stake in shares of uniQure during the third quarter worth approximately $50,000. FNY Investment Advisers LLC grew its position in shares of uniQure by 76.7% in the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 718 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in shares of uniQure by 358.0% during the second quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 5,538 shares during the period. 78.83% of the stock is owned by institutional investors.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.